OS Therapies (OSTX) Research & Development (2023 - 2025)
OS Therapies' (OSTX) quarterly Research & Development came in at -$7.6 million in Q4 2025, down 301.93% YoY from $3.7 million in Q4 2024, and down 301.42% on a QoQ basis from $3.8 million in Q3 2025.
OS Therapies (OSTX) Research & Development (2023 - 2025) Analysis & Trends
OS Therapies (OSTX) has 3 years of Research & Development data on file, last reported at -$7.6 million in Q4 2025.
- Quarterly Research & Development fell 301.93% year-over-year to -$7.6 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 375.85% YoY) and the FY2024 annual result came in at $86687.0, down 97.31% from the prior year.
- Research & Development fell to -$7.6 million in Q4 2025, from $3.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $3.8 million in Q3 2025 to a low of -$7.6 million in Q4 2025.
- A 3-year average of $181610.5 and a median of $753784.0 in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 530.28% in 2025, down 301.93% in 2025.
- Tracing OSTX's Research & Development over 3 years: stood at $1.0 million in 2023, then tumbled by 284.68% to -$1.9 million in 2024, then slumped by 301.93% to -$7.6 million in 2025.
- The last three Research & Development figures came in at -$7.6 million (Q4 2025), $3.8 million (Q3 2025), and $2.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | 6.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.56 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 2.50 Mn |
| Dec 31, 2024 | -1.88 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 396,567.00 |
| Mar 31, 2024 | 361,809.00 |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 454,505.00 |
| Jun 30, 2023 | 992,896.00 |
| Mar 31, 2023 | 753,784.00 |